Denmark’s pharmaceutical industry was the dominant force behind the country’s economic growth in the first quarter of 2026, according to Lif Lægemiddelindustriforeningen, the Danish Pharmaceutical Industry Association.
Recent data from Statistics Denmark found that Danish GDP grew by 1.9% in the first quarter of 2026 after adjusting for prices and seasonal effects, in what was one of the strongest quarterly performances in Europe.
However, the association noted that the broader economy outside pharmaceuticals expanded by just 0.2% when measured by gross value added, underlining the outsized contribution of the life sciences sector.
‘A wild start’
“We are seeing a wild start to the year,” commented Thomas Senderovitz, CEO of Lif Lægemiddelindustriforeningen. “It is remarkable how much the pharmaceutical industry is contributing to the Danish economy right now.
“The high level of activity and exports is helping to lift growth significantly – even at a time when companies are experiencing tremendous pressure on competitiveness and challenging market conditions.”
According to the association, much of the increase in Danish exports came from higher pharmaceutical output alongside gains in trade and transport services.
Global position of strength
Senderovitz said the figures demonstrated Denmark’s ‘global position of strength’ within life sciences, but warned that maintaining growth would require safeguarding investment in favourable conditions for research, manufacturing and exports.
“The results speak for themselves: the pharmaceutical industry is one of Denmark’s most important growth engines,” he noted. “But if we are to continue to contribute on the same scale in the future, it requires that Denmark maintains its competitiveness and ensures attractive conditions for research, production and export.”
Lif Lægemiddelindustriforeningen is the trade association for research-based domestic and international pharmaceutical companies in Denmark. Read more here.
